Six approved products in this class give six different answers. Two of them are the same molecule in the same kind of weekly injection, and they disagree by a factor of two and a half: one allows five days to catch up, the other allows forty-eight hours.
The research peptides have no answer at all. That gap is the useful part of this page.
What do the labels say if you miss a weekly dose?
Each label sets a deadline for a missed weekly dose and says what to do on either side of it. Wegovy is the strictest. It instructs taking the missed dose "as soon as possible" when "the next scheduled dose is more than 2 days away (48 hours)," and not taking it when the next dose is "less than 2 days away (48 hours)."1 Either way the schedule itself does not move.
Ozempic is the most forgiving, and it holds the same drug. Its label says to inject "as soon as possible within 5 days after the missed dose," and that beyond five days the patient should "skip the missed dose and administer the next dose on the regularly scheduled day."2 Five days against forty-eight hours, for semaglutide either way.
Tirzepatide sits between the two. Its label instructs patients to inject "as soon as possible within 4 days (96 hours)" after the missed dose, and if "more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day."3 Dulaglutide sits between the two at three days, with the clock running the other way: take it "if there are at least 3 days (72 hours) until the next scheduled dose," skip it otherwise.4 All three weekly labels then close on the same sentence, that patients "can then resume their regular once weekly dosing schedule."34
Four weekly products, four deadlines, two different things being measured. Ozempic and tirzepatide count forward from the dose that was missed, allowing five days and four days after it. Dulaglutide and Wegovy count backward from the dose not yet taken, asking how much of the gap is left. Those are not the same question in a different order, because the same calendar gap can sit inside one rule and outside another, and no label converts between the two. A patient who learned the rule on one drug and switched to another is working from the wrong clock as well as the wrong number.
Two of the labels also lean on a phrase none of them defines. Semaglutide says to take the missed dose "as soon as possible," and tirzepatide says "as soon as possible within 4 days (96 hours)."13 The hour count is precise. What counts as soon as possible inside it is left to the reader.
How much time do you have, drug by drug?
Between 48 hours and five days, depending on the product.
| Product | Schedule | Elimination half-life | What its label says about a missed dose |
|---|---|---|---|
| Semaglutide injection (Wegovy) | Weekly | "approximately 1 week"1 | Take it if the next dose is more than 48 hours away, skip it if less1 |
| Semaglutide injection (Ozempic) | Weekly | Same molecule as above | Take it "within 5 days after the missed dose," skip it beyond that2 |
| Tirzepatide injection (Mounjaro) | Weekly | "approximately 5 days"3 | Take it within 96 hours of the missed dose, otherwise skip3 |
| Dulaglutide injection (Trulicity) | Weekly | "approximately 5 days"4 | Take it if at least 72 hours remain until the next dose, otherwise skip4 |
| Liraglutide injection (Saxenda) | Daily | "approximately 13 hours"5 | Resume at the next scheduled dose, with no extra dose to make up for it5 |
| Semaglutide tablets | Daily | Not quoted here | "skip the missed dose and take the next dose the following day"6 |
Every figure in that table is quoted from the prescribing information of the product named. None of it is a recommendation from this site. None of it transfers to a compound that has no label. Two rows of it are the same drug.
Does a longer half-life buy you a longer window?
No, and half-life cannot be the thing setting the window, because one molecule holds both extremes. Semaglutide has the longest half-life here at "approximately 1 week," with the label adding that the drug "will be present in the circulation for about 5 to 7 weeks after the last dose of 2.4 mg."1 That same molecule carries the most generous rule in the set at five days and the strictest at forty-eight hours, depending only on which of its two injection labels a person is reading.21
Tirzepatide clears faster at "approximately 5 days" and lands in between at four.3 Were these windows a reading of blood levels, that ordering would be impossible.
Why do two drugs with the same half-life have different rules?
Tirzepatide and dulaglutide are the clean test, because both labels report an elimination half-life of about five days.34 One allows 96 hours after the missed dose. Dulaglutide allows the dose only if 72 hours remain before the next one. Deadlines differ between them. So does the event each one is counted from, for two drugs matched on the single pharmacokinetic number most people would reach for.
Indication is the likelier explanation, and the labels do not confirm it. Wegovy and Ozempic hold semaglutide at different approved doses for different approved uses, and the stricter rule sits with the higher-dose weight-management product. Whether that reflects something measured or something decided, no document quoted here says.
Nobody can rederive one of these windows at home from a half-life. This matters past trivia, because people carry the rule they remember from one product across to another, and someone who forgot a shot and reaches for a half-remembered number is quite likely reaching for a different product's rule.
A missed-dose window is therefore a clinical and regulatory judgment about what a sponsor studied and what the agency approved for that specific product.
Does the oral version follow the same rule?
The oral version makes a third semaglutide rule. Tablet labeling says "If a dose is missed, skip the missed dose and take the next dose the following day."6 One molecule, three approved products, three instructions: skip it entirely, take it within five days, or take it only when the next dose is more than forty-eight hours off.621
The oral difference has an obvious defense. Miss a day of a daily drug and one dose of seven is gone that week, so there is little to recover. Miss a week of a weekly drug and the week is gone entirely. No such defense covers the two injections. They share a molecule, a route and a weekly schedule, and still disagree.
Manufacturer does not rescue it either. All three semaglutide products are Novo Nordisk, and the two Lilly products, tirzepatide and dulaglutide, carry rules that differ in deadline and in direction. Whatever sets the window, it is set per product and not per company or per molecule.
What does a daily injectable's rule look like?
Shorter, with a second rule sitting behind it. The liraglutide label says to "resume the once-daily regimen as prescribed with the next scheduled dose," and adds that no extra dose should be given to make up for the one missed.5 At a half-life of "approximately 13 hours," a missed day is most of the drug gone, so there is little to correct for.5
The second rule appears a few lines later and has nothing to do with blood levels. If "more than 3 days have elapsed since the last SAXENDA dosage," the label says to reinitiate at the 0.6 mg starting dose and work through the escalation schedule again.5 Three days off a daily drug sends a patient back to the beginning for a stated reason: to "reduce the risk of gastrointestinal adverse reactions."5 The concern is nausea, not efficacy.
What does reinitiating at the starting dose mean?
Reinitiating means climbing back up from the starting dose, on tolerability grounds. The semaglutide injection label carries its own version for longer gaps. After "2 or more consecutive doses are missed," it allows resuming as scheduled or reinitiating the drug and following the dose escalation schedule, and it attaches the same kind of reason, reducing the occurrence of gastrointestinal symptoms.1
Both labels treat tolerance as something built over weeks that fades once dosing stops. The escalation schedule exists because starting at a full dose makes people sick. A long enough gap puts someone back in the position of a person starting out. How long that takes, and how far tolerance falls in the meantime, goes unstated in both documents.
Can you change which day you inject?
Three of the labels address it and set a minimum gap, and they do not agree on the gap. Ozempic: the day "can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours)."2 Tirzepatide: "at least 3 days (72 hours)."3 Dulaglutide: the last dose must have been "administered 3 or more days before the new day of administration."4
Wegovy carries no equivalent sentence at all, and the timing guide covers the related question of which day and hour to pick. Its administration section says the drug is taken "on the same day each week," and that the time of day and the injection site "can be changed without dose adjustment."1 So the same molecule in the same weekly injection has an explicit 48-hour rule under one brand and nothing under the other. That absence may be deliberate or it may be an oversight, and nothing in the document settles it either way.
What do the labels say about doubling up?
One says it outright and the rest say it by structure. The liraglutide label is explicit: "Do not administer an extra dose or increase the dose to make up for the missed dose."5 The three weekly labels never raise the possibility at all. Their instruction resolves to take it or skip it, and no sentence in any of them describes adding a missed dose to a scheduled one, or splitting the difference with something in between.
Why none of them entertains it is visible in the parts of the same labels that deal with starting out. Every one of these products is escalated over weeks instead of started at the full dose, and the two labels that explain a step back down after an interruption both give a gastrointestinal reason.15 A doubled dose is the situation those schedules exist to avoid. What the labels document about a sudden larger exposure concerns tolerance and not efficacy. What a doubled dose would actually do goes unreported in all six.
How much does one missed week change blood levels?
One missed week changes blood levels less than the worry around it suggests, at least for the longest-acting products, though no label quantifies the gap. The semaglutide figure gives the scale: circulating drug "for about 5 to 7 weeks after the last dose."1 On a weekly schedule, one missed injection lands against a background of accumulated drug that takes more than a month to clear.
That is pharmacokinetics and not outcomes, and the onset guide covers the related question of how long these drugs take to do anything in the first place. No label on this page reports what a missed dose does to weight loss, to blood sugar or to side effects. Instructions are published. Consequences are not, and no label on this page draws that distinction for the reader.
Is there a missed-dose rule for a research peptide?
None exists, for any of them. Missed-dose sections live in prescribing information, and prescribing information is a document the FDA approves at the end of a development program. Retatrutide has no approved label. Neither does BPC-157, nor anything else in this library carrying a research-use-only designation, a status the legality guide sets out. What circulates instead is a mix of inference from the approved drugs and advice passed between users, and the first of those is the more plausible-sounding of the two. The comparison above is the reason to distrust it: inference from one approved drug to another already fails among products that have the full evidence behind them.
Six approved products carry six published answers. Across the rest of the site that count drops to zero.
Why is there no rule without a label?
The rule is an output of the trials and not an input to them, and a label is where that output gets printed. Sponsors arrive at a missed-dose window from pharmacokinetic modeling, from what happened to the people in the trials who missed doses, and from the tolerability data standing behind the escalation schedule. That evidence accumulates over years and gets reviewed before the sentence reaches a label.
For a compound with no completed human program, none of those inputs exist. A half-life may be estimated, sometimes from animals, often from a single small study, and the dosage chart marks where every figure on this site comes from. An estimated half-life does not yield a missed-dose rule in any case. The two Lilly drugs settle that between them: one shared half-life produced two different rules even where the full evidence existed.
What have the labels not measured?
Labels have not measured the size of the effect, for any of the six products.
Labels say what to do without saying what it costs to do otherwise. None of the six reports how far a skipped week moves weight, blood sugar or anything else a person is taking the drug for, and none reports how many people in the trials missed doses or what happened to their results. A missed-dose instruction is a practical convention built on pharmacokinetics and tolerability, and it was never a measurement of consequences. Reading one as a warning about lost progress reads something into it that is not there.
For research compounds the gap is wider and plainer. No missed-dose window has been published, no study has reported what happens when the schedule slips, and nothing on this page supplies either. Every rule above describes a specific approved product at specific approved doses, and the six of them do not even agree with each other.
Common questions
What happens if you miss a dose of semaglutide?
Semaglutide has three approved products and three different rules. Wegovy sets a 48-hour rule, counted toward the next scheduled dose. Ozempic allows five days after the missed one. The tablet labeling says to skip it and take the next dose the following day.
How late can an Ozempic dose be?
Ozempic's label allows five days after the missed dose, and past that point it says to skip the dose and carry on with the regular schedule. No product here gets longer, and Wegovy holds the same drug with the shortest window of all.
How late can a tirzepatide dose be?
Tirzepatide's label allows four days. It instructs taking the missed dose "as soon as possible within 4 days (96 hours)," and skipping it after that point, with the regular weekly schedule resuming either way.
Why is the tirzepatide window longer than the semaglutide one?
Neither label explains the difference, and half-life does not account for it. Semaglutide is the longer-acting of the two, at about a week against about five days, and yet it carries the shorter window.
Can you take two doses to catch up?
Nothing in the five labels describes doing that. Liraglutide's states it directly, ruling out an extra dose or an increased dose to make up for a missed one. The weekly labels offer only take it or skip it.
What if you miss two weeks in a row?
Semaglutide's injection label addresses that case. After two or more consecutive missed doses it allows resuming as scheduled, or reinitiating the drug and following the escalation schedule again to reduce gastrointestinal symptoms.
Can you change your injection day?
Three labels allow it and set different minimums. Ozempic requires at least two days between doses, tirzepatide and dulaglutide at least three. Wegovy has no equivalent sentence and says only that the drug is taken on the same day each week.
Does a missed dose mean starting the escalation over?
Only after a long enough gap, and only where a label says so. Liraglutide sets the trigger at more than three days, returning to 0.6 mg daily. Semaglutide offers reinitiation as an option after two or more missed weekly doses.
Why does the escalation restart at all?
Tolerability, according to both labels that give a reason. Liraglutide's label names the risk of gastrointestinal adverse reactions, and semaglutide's names the occurrence of gastrointestinal symptoms. Neither reason concerns how well the drug works.
Is there a missed-dose rule for retatrutide?
Retatrutide has no approved label, so no missed-dose section exists for it. Every rule on this page belongs to a specific approved product and does not carry across.
Does BPC-157 have a dosing schedule to miss?
BPC-157 has no approved label and no published human dosing schedule, a gap the evidence guide covers in full. A missed-dose rule needs a dosing rule underneath it.
Why do labels give hours rather than days?
Hours remove the argument about when a day begins. All the weekly labels pair the plain-language figure with an hour count, writing "2 days away (48 hours)" and "4 days (96 hours)."
Does a longer half-life always mean more room for error?
Half-life cannot be setting these windows, because semaglutide holds both the longest and the shortest of them at the same half-life of about one week. Tirzepatide and dulaglutide make the same point from the other side, sharing a half-life of about five days and carrying different rules.
How long does semaglutide stay in the body after the last injection?
Its label gives five to seven weeks after a final 2.4 mg dose, alongside an elimination half-life of about one week. That figure describes presence in the circulation and not continued effect. The label does not quantify the second one after stopping.
Does any label say what a missed dose costs you?
No label quoted on this page reports an outcome for a missed dose. Each gives an instruction without attaching a figure for weight loss, blood sugar or side effects.
Sources
- Wegovy (semaglutide) injection, US prescribing information, sections 2.1, 2.4 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. Missed-dose instructions and the 48-hour threshold, reinitiation after two or more missed doses, the elimination half-life of approximately 1 week, and presence in the circulation for about 5 to 7 weeks after the last 2.4 mg dose. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11
- Ozempic (semaglutide) injection, for subcutaneous use, US prescribing information, section 2.1. Read at source on DailyMed, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79. The 5-day missed-dose window and the minimum of at least 2 days (>48 hours) between doses when the weekly day is changed. Taken from the subcutaneous injection record, distinct from the semaglutide tablet records returned by the openFDA brand search. ↩1 ↩2 ↩3 ↩4 ↩5
- Mounjaro (tirzepatide) injection, US prescribing information, sections 2.1 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The 96-hour missed-dose window, the 72-hour minimum for changing the day of administration, and the elimination half-life of approximately 5 days. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
- Trulicity (dulaglutide) injection, US prescribing information, sections 2.3 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The 72-hour missed-dose threshold, the three-day minimum for changing the day of administration, and the elimination half-life of approximately 5 days. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6
- Saxenda (liraglutide) injection, US prescribing information, sections 2.1 and 12.3. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. Resuming the once-daily regimen with no extra dose, reinitiation at 0.6 mg after more than 3 days, the stated reason of reducing gastrointestinal adverse reactions, and the elimination half-life of approximately 13 hours. ↩1 ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8
- Semaglutide tablets, US prescribing information, section 2.1, Important Administration Instructions. Read at source via the openFDA drug label API, https://api.fda.gov/drug/label.json. The records returned for this brand search are tablet products and the quoted missed-dose sentence appears in the tablet labeling. No half-life figure from this label is quoted on this page. ↩1 ↩2 ↩3